|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.46 USD | +0.62% |
|
-0.77% | +4.19% |
| Apr. 17 | Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating | MT |
| Apr. 05 | Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target | MT |
Jan 8 (Reuters) - Ardelyx Inc:
* ARDELYX PROVIDES UPDATE ON GROWING COMMERCIAL MOMENTUM AND 2024 STRATEGIC PRIORITIES
* ARDELYX INC - IBSRELA(®) NOW EXPECTED TO GENERATE GREATER THAN $1.0 BILLION IN ANNUAL U.S. NET PRODUCT SALES REVENUE AT PEAK
* ARDELYX INC - ARDELYX CURRENTLY EXPECTS FULL-YEAR 2024 U.S. NET PRODUCT SALES REVENUE FOR IBSRELA TO BE BETWEEN $140.0 AND $150.0 MILLION Source text for Eikon: Further company coverage:
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 197.1 GBX | +0.41% | +0.15% | 4.98B | ||
| 100.8 GBX | -.--% | -.--% | 2.15B | ||
| 6.46 USD | +0.62% | -0.77% | 1.49B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +4.19% | 1.49B | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
ARDELYX, INC. 
